Clinical Research in Cardiology

, Volume 97, Issue 2, pp 74–82

Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised

  • Torsten Becker
  • Thomas Kleemann
  • Margit Strauss
  • Klaus  Doenges
  • Steffen Schneider
  • Jochen Senges
  • Karlheinz Seidl
ORIGINAL PAPER

Abstract

Aims

We evaluated the prognostic impact of a first episode of symptomatic atrial fibrillation under real life conditions.

Background

Most studies regarding the treatment and long-term outcome of patients with atrial fibrillation mainly refer to patients with recurrent episodes. In contrast, data on the prognostic implications of a first episode of atrial fibrillation are scarce.

Methods

Over a follow-up period of 5 years, we analyzed 1053 patients, initially scheduled for cardioversion of symptomatic atrial fibrillation, who were included into the prospective registry ANTIK (Ludwigshafener ANTIKoagulationsstudie).

Results

Of those, 618 patients (59%) were included with a first episode of symptomatic atrial fibrillation whereas 435 patients (41%) presented with recurrent episodes. As a consequence of referral for cardioversion of symptomatic atrial fibrillation, structural heart disease was newly diagnosed in a significantly higher proportion of patients with a first episode (27 vs 13%, OR 2.4, 95% CI 1.7–3.3) and patients with a first episode were more likely to have an EF≤40% (21 vs 15%, OR 1.5, 95% CI 1.1-2.2). After 5 years, the mortality rate for patients with a first episode was higher than for those with recurrent episodes (27 vs 16%, OR 2.0, 95% CI 1.4–2.7). In the multivariate analysis, a first episode also was independently associated with an increased longterm mortality (HR 1.4, 95% CI 1.02–1.98). In contrast to patients with recurrent episodes, a first episode was associated with a significantly higher mortality, when compared to an age-matched control group calculated from mortality tables.

Conclusion

The first episode of symptomatic atrial fibrillation intended for cardioversion serves as a marker for underlying cardiac diseases and is associated with impaired prognosis.

Key words

atrial fibrillation first episode prognosis risk marker 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators (2005) Ximelagatran vs Warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial (SPORTIF V). JAMA 293:690–698PubMedCrossRefGoogle Scholar
  2. 2.
    The AFFIRM Investigators (2002) Baseline characteristics of patients with atrial fibrillation: the AFFIRM study. Am Heart J 143:991–1001CrossRefGoogle Scholar
  3. 3.
    The AFFIRM Investigators (2004) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109:1509–1513CrossRefGoogle Scholar
  4. 4.
    Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA (1994) Independent risk factors for atrial fibrillation in a populationbased cohort: the framingham heart study. JAMA 271:840–844PubMedCrossRefGoogle Scholar
  5. 5.
    Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death. Circulation 98:946–952PubMedGoogle Scholar
  6. 6.
    Bernhardt P, Schmidt H, Sommer T, Lüderitz B, Omran H (2006) Atrial fibrillation – patients at high risk for cerebral thromboembolism. Clin Res Cardiol 95:148–153PubMedCrossRefGoogle Scholar
  7. 7.
    Brugada P (2006) What evidence do we have to replace in-hospital implantable cardioverter defibrillator follow-up? Clin Res Cardiol 95 (Suppl 3):iii3–9PubMedCrossRefGoogle Scholar
  8. 8.
    Conradi G, Deetjen A, Möllmann S, Hamm CW, Dill T (2006) Symptomatic atrial fibrillation as the first symptom of a giant left atrial appendage aneurysm. Clin Res Cardiol 95:614–616PubMedCrossRefGoogle Scholar
  9. 9.
    Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 32:965–703CrossRefGoogle Scholar
  10. 10.
    Finsterer J, Stöllberger C, Krugluger W (2007) Positive troponin-T in noncompaction is associated with neuromuscular disorders and poor outcome. Clin Res Cardiol 96:109–113PubMedCrossRefGoogle Scholar
  11. 11.
    Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M, Barrell P (2005) AFFIRM Investigators. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation on Rhythm Management (AFFIRM) study. Am Heart J 149:657–663PubMedCrossRefGoogle Scholar
  12. 12.
    FusterV, Rydén LE, Cannorn DS, Crijns HJ, Curtis AB et al (2006) ACC/AHA/ ESC guidelines for the management of patients with atrial fibrillation. A report of the American college of cardiology/ American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 48:e149–246CrossRefGoogle Scholar
  13. 13.
    Fuster V, Rydén LE, Gibbons RJ, Antman EM, Klein WW et al (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/ American heart association taskforce on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American society for pacing and electrophysiology. J Am Coll Cardiol 38:1266i–1266ixxCrossRefGoogle Scholar
  14. 14.
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 285:2864–2870PubMedCrossRefGoogle Scholar
  15. 15.
    Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019–1026PubMedCrossRefGoogle Scholar
  16. 16.
    Jouven X, Desnos M, Guerot C, Ducimetiere P (1999) Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I. Eur Heart J 20:896–899PubMedCrossRefGoogle Scholar
  17. 17.
    Kettering K, Greil GF, Busch M, Miller S, Sieverding L, Schreieck J (2006) Catheter ablation of atrial fibrillation: ongoing atrial fibrillation inside a single pulmonary vein after successful electrical disconnection and restoration of sinus rhythm in both atria. Clin Res Cardiol 95:663–667PubMedCrossRefGoogle Scholar
  18. 18.
    Kleemann T, Becker T, Dönges K, Vater M, Gut B, Schneider S, Senges J, Seidl K (2007) The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease. Clin Res Cardiol 96:103–108PubMedCrossRefGoogle Scholar
  19. 19.
    Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the mannitoba follow-up study. Am J Med 98:476–484PubMedCrossRefGoogle Scholar
  20. 20.
    Langer C, Piper C, Vogt J, Heintze J, Butz T, Lindner O, Burchert W, Kersting C, Horstkotte D (2007) Atrial fibrillation in carcinoid heart disease – the role of serotonin. A review of the literature. Clin Res Cardiol 96:114– 118PubMedCrossRefGoogle Scholar
  21. 21.
    Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, Sebaoun A for the College of French Cardiologists (1999) Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA Study. Circulation 99:3028–3035PubMedGoogle Scholar
  22. 22.
    Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB (1996) Stroke severity in atrial fibrillation: the framingham heart study. Stroke 27:1760–1764PubMedGoogle Scholar
  23. 23.
    Lip GYH (1999) Atrial fibrillation and mortality. Eur Heart J 20:1525–1527PubMedCrossRefGoogle Scholar
  24. 24.
    Obergassel L, Lawrenz T, Gietzen FH, Lieder F, Leuner C, Kuhn H, Stellbrink C (2006) Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation. Clin Res Cardiol 95:254–260PubMedCrossRefGoogle Scholar
  25. 25.
    Ostranderld JR, Brandt RL, Kjelsberg MO, Epstein FH (1965) Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 31:888–898Google Scholar
  26. 26.
    Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG (1996) Management of patients with atrial fibrillation. A statement for healthcare professionals. From the subcommittee on electrocardiography and electrophysiology. American Heart Association. Circulation 93:1262–1277PubMedGoogle Scholar
  27. 27.
    Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM (1997) Incidence and risk factors for atrial fibrillation in older adults. Circulation 96:2455–2461PubMedGoogle Scholar
  28. 28.
    Reibis RK, Dovifat C, Dissmann R, Ehrlich B, Schulz S, Stolze K, Wegscheider K, Völler H (2006) Implementation of evidence-based therapy in patients with systolic heart failure from 1998–2000. Clin Res Cardiol 95:154–161PubMedCrossRefGoogle Scholar
  29. 29.
    Ricci RP, Russo M, Santini M (2006) Management of atrial fibrillation – what are the possibilities of early detection with home monitoring? Clin Res Cardiol 95(Suppl 3):iii10–16PubMedCrossRefGoogle Scholar
  30. 30.
    Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, Havranek E, Murray K, Olshansky B, O’Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler M, Nasco EM, Greene HL and the AFFIRM Investigators (2004) Analysis of cause-specific mortality in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109:1973–1980PubMedCrossRefGoogle Scholar
  31. 31.
    Stewart S, Hart CL, Hole DJ, McMurray JJ (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:359–364PubMedCrossRefGoogle Scholar
  32. 32.
    Strohmer B, Schernthaner C, Pichler M (2006) Simultaneous angiographic imaging of ipsilateral pulmonary veins for catheter ablation of atrial fibrillation. Clin Res Cardiol 95:591–599PubMedCrossRefGoogle Scholar
  33. 33.
    Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ for the RACE Study group (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation (RACE). N Engl J Med 347:1834–1840PubMedCrossRefGoogle Scholar
  34. 34.
    Vaughan-Williams EM (1984) A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 24:129–147PubMedGoogle Scholar
  35. 35.
    Vidaillet H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, Sharma P, Smith PN, Hayes J (2002) A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 113:365–370PubMedCrossRefGoogle Scholar
  36. 36.
    Wang TJ, Larson MG, Levy D, Ramachandran SV, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham Heart Study. Circulation 107:2920–2925PubMedCrossRefGoogle Scholar
  37. 37.
    Wyse DJ, Waldo AL, DiMarco JP, Domanski MJ, Rosenebrg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE Corley SD for The AFFIRM Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833PubMedCrossRefGoogle Scholar
  38. 38.
    Statistisches Bundesamt (2006) Periodensterbetafeln für Deutschland: Allgemeine und abgekürzte Sterbetafeln von 1871/1881–2002/2004, Wiesbaden. http://www-ec.destatis.de/csp/ shop/sfg/vollanzeige.csp?ID=1017978Google Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  • Torsten Becker
    • 1
  • Thomas Kleemann
    • 1
  • Margit Strauss
    • 1
  • Klaus  Doenges
    • 1
  • Steffen Schneider
    • 2
  • Jochen Senges
    • 1
  • Karlheinz Seidl
    • 1
  1. 1.Klinikum der Stadt LudwigshafenHerzzentrumLudwigshafenGermany
  2. 2.Stiftung Institut für HerzinfarktforschungLudwigshafenGermany

Personalised recommendations